Filip Baert

Summary

Country: Belgium

Publications

  1. doi request reprint Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease
    Filip Baert
    Department of Gastroenterology, H Hartziekenhuis Roeselare Menen vzw, Roeselare, Belgium
    Gastroenterology 138:463-8; quiz e10-1. 2010
  2. doi request reprint Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients
    Filip Baert
    Department of Internal Medicine, H Hart ziekenhuis Roeselare Menen, Belgium
    J Crohns Colitis 7:154-60. 2013
  3. pmc Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas
    Nancy Van Damme
    Department of Hepato Gastroenterology, Digestive Oncology Unit, Ghent University Hospital, De Pintelaan 185 1K12IE, 9000 Ghent, Belgium
    BMC Cancer 10:189. 2010
  4. doi request reprint Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 16:243-9. 2010
  5. pmc Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
    Severine Vermeire
    Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gut 56:1226-31. 2007
  6. ncbi request reprint Medical therapy for Crohn's disease: top-down or step-up?
    Filip Baert
    Department of Gastroenterology, Hospital of Leuven, Belgium
    Dig Dis 25:260-6. 2007
  7. ncbi request reprint Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial
    Paul Rutgeerts
    Department of Gastroenterology, University Hospital Gasthuisberg, 3000 Leuven, Belgium
    Gastroenterology 128:856-61. 2005
  8. doi request reprint Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
    Geert D'Haens
    Department of Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands
    Inflamm Bowel Dis 18:2218-24. 2012
  9. ncbi request reprint Immunogenicity of infliximab: how to handle the problem?
    Filip Baert
    Department of Gastroenterology, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium
    Acta Gastroenterol Belg 70:163-70. 2007
  10. ncbi request reprint Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
    Filip Baert
    Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    N Engl J Med 348:601-8. 2003

Collaborators

Detail Information

Publications10

  1. doi request reprint Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease
    Filip Baert
    Department of Gastroenterology, H Hartziekenhuis Roeselare Menen vzw, Roeselare, Belgium
    Gastroenterology 138:463-8; quiz e10-1. 2010
    ..Few prospective data are available to support the clinical relevance of mucosal healing in patients with Crohn's disease. This study examined whether complete healing, determined by endoscopy, predicts a better outcome in Crohn's disease...
  2. doi request reprint Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients
    Filip Baert
    Department of Internal Medicine, H Hart ziekenhuis Roeselare Menen, Belgium
    J Crohns Colitis 7:154-60. 2013
    ..Attempts for dose de-escalation have not been studied. This study aimed to assess the need for, predictors, and outcome of dose escalation and de-escalation in a large cohort of adalimumab treated Crohn's patients...
  3. pmc Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas
    Nancy Van Damme
    Department of Hepato Gastroenterology, Digestive Oncology Unit, Ghent University Hospital, De Pintelaan 185 1K12IE, 9000 Ghent, Belgium
    BMC Cancer 10:189. 2010
    ..The aim of this study was to analyse EGFR expression, EGFR gene copy number and EGFR and K-RAS mutations in two cohorts of squamous cell carcinomas, specifically anal canal and tonsil carcinomas...
  4. doi request reprint Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 16:243-9. 2010
    ..In case reports, thiopurine analogs and infliximab (IFX) have been proposed as effective therapy in this setting. We analyzed the long-term efficacy of IFX in Belgian patients with refractory pouch complications...
  5. pmc Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
    Severine Vermeire
    Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gut 56:1226-31. 2007
    ..Concomitant use of immunosuppressives (IS) reduces the risk of ATI formation...
  6. ncbi request reprint Medical therapy for Crohn's disease: top-down or step-up?
    Filip Baert
    Department of Gastroenterology, Hospital of Leuven, Belgium
    Dig Dis 25:260-6. 2007
    ..Lack of markers able to identify high-risk patients, discussions about long-term safety and the high costs of infliximab are further factors supporting a more careful approach to the management of CD...
  7. ncbi request reprint Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial
    Paul Rutgeerts
    Department of Gastroenterology, University Hospital Gasthuisberg, 3000 Leuven, Belgium
    Gastroenterology 128:856-61. 2005
    ..We investigated the efficacy and safety of ornidazole, a nitroimidazole antibiotic, for the prevention of clinical recurrence of Crohn's disease after curative ileocolonic resection in a placebo-controlled double-blind clinical trial...
  8. doi request reprint Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
    Geert D'Haens
    Department of Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands
    Inflamm Bowel Dis 18:2218-24. 2012
    ..Fecal calprotectin is a marker of inflammation in inflammatory bowel disease (IBD). Since mucosal healing has become a goal of treatment in IBD we examined how reliably calprotectin levels reflect mucosal disease activity...
  9. ncbi request reprint Immunogenicity of infliximab: how to handle the problem?
    Filip Baert
    Department of Gastroenterology, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium
    Acta Gastroenterol Belg 70:163-70. 2007
    ..Antibody formation is associated with allergic reactions and loss of response...
  10. ncbi request reprint Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
    Filip Baert
    Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    N Engl J Med 348:601-8. 2003
    ..We evaluated the clinical significance of these antibodies in patients with Crohn's disease...